revascularization

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

Initial Complete Revascularization vs. Staged Revascularization in Patients with STEMI and Multivessel Disease

In patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (primary PCI), multivessel disease is observed in up to 40% of cases. The optimal timing for revascularizing non-culprit lesions in these patients without cardiogenic shock remains a controversial issue. European guidelines recommend completing revascularization during the initial procedure or within 45&nbsp;days<a href="https://solaci.org/en/2024/07/17/initial-complete-revascularization-vs-staged-revascularization-in-patients-with-stemi-and-multivessel-disease/" title="Read more" >...</a>

Revascularization Timing in Acute Coronary Syndrome

Multivessel disease is often present in ST elevation acute myocardial infarction (STEMI) patients. The AHA/ACC 2021 revascularization guidelines recommend staged complete revascularization as class I, single-setting complete revascularization as class 2b, and recommend against culprit only revascularization. At present, we have more randomized studies (BIOVASC, FIRE and MULTISTAR) comparing staged vs single-setting complete revascularization, but<a href="https://solaci.org/en/2024/07/16/revascularization-timing-in-acute-coronary-syndrome/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

Functional Assessment Using QFR for the Revascularization of Non-Culprit Lesions in AMI Patients

Nowadays, evidence from studies and meta-analyses has demonstrated the benefits of complete revascularization compared to culprit-vessel-only revascularization in patients with acute myocardial infarction (AMI). The identification and treatment of non-culprit lesions can be guided by conventional angiography, intracoronary imaging, or coronary physiology; the optimal modality, however, is still unclear. Quantitative flow ratio (QFR) is a<a href="https://solaci.org/en/2024/05/22/functional-assessment-using-qfr-for-the-revascularization-of-non-culprit-lesions-in-ami-patients/" title="Read more" >...</a>

EuroPCR 2024 | Complete revascularization affects clinical outcomes? REVIVED.BCIS2 Insights

Complete revascularization has shown in several studies and meta-analysis a benefit in mortality vs. incomplete revascularization. The REVIVED-BCIS looked at whether there were differences in mortality and hospitalization for cardiac failure in patients with ventricular function deterioration and viability when comparing coronary angioplasty(PCI) against optimal medical treatment. This study showed that PCI was not associated<a href="https://solaci.org/en/2024/05/17/europcr-2024-complete-revascularization-affects-clinical-outcomes-revived-bcis2-insights/" title="Read more" >...</a>

¿La elevación de marcadores luego de una angioplastia electiva no debería preocuparnos?

EXCEL Study: Complete vs. Incomplete Revascularization

Regardless of whether it is attempted through percutaneous coronary intervention (PCI) or myocardial revascularization surgery (MRS), complete revascularization (CR) is not always achieved. Overall, it is more frequent with surgery than with percutaneous treatment. Additionally, incomplete revascularization (IR) has proven to be associated with worse outcomes compared to CR. Researchers conducted an analysis of the<a href="https://solaci.org/en/2024/04/24/excel-study-complete-vs-incomplete-revascularization/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis

In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and<a href="https://solaci.org/en/2024/02/22/recurrent-revascularization-at-10-years-after-percutaneous-treatment-of-des-in-stent-restenosis/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

Sub-Analysis of the REVIVED-BCIS2: Myocardial Viability Changes Prognosis in Ischemic Cardiomyopathy Revascularization?

The purpose of myocardial viability testing is to identify patients that might benefit from revascularization by diagnosing three types of myocardium: normal, viable or hibernating, and scarred (non-viable). Non-randomized studies have shown recovery of a viable ventricle after myocardial revascularization surgery (CABG) and improved survival.&nbsp; However, a sub-analysis of the main study on viability testing,<a href="https://solaci.org/en/2024/02/10/sub-analysis-of-the-revived-bcis2-myocardial-viability-changes-prognosis-in-ischemic-cardiomyopathy-revascularization/" title="Read more" >...</a>

Events According to Revascularization Modality in the ISCHEMIA Trial

The main studies carried out on patients with chronic coronary syndromes (CCS), such as the MASS II, COURAGE, BARI 2D and FAME-2, failed to show benefits in terms of mortality with the invasive approach.&nbsp; The ISCHEMIA, a large randomized study including patients with moderate to severe ischemia, with without left main disease and with acceptable<a href="https://solaci.org/en/2024/01/31/events-according-to-revascularization-modality-in-the-ischemia-trial/" title="Read more" >...</a>

La ATC es una alternativa válida en el TCI

Revascularization vs. Deferral of Physiologically Significant Lesions in the Left Main Coronary Artery

Most randomized studies on decision-making in coronary artery disease revascularization exclude left main coronary artery disease (LMCAD), as did the ISCHEMIA Study. On the other hand, the benefits of functionally assessing lesions, proven in studies such as FAME, emphasize the importance of this tool in guiding revascularization decisions. However, there is still little understanding of<a href="https://solaci.org/en/2023/12/06/revascularization-vs-deferral-of-physiologically-significant-lesions-in-the-left-main-coronary-artery/" title="Read more" >...</a>

Cilostazol en pacientes diabéticos con revascularización periférica endovascular: Un paso más allá de la mejoría sintomática

Cilostazol in Diabetic Patients with Endovascular Peripheral Revascularization: One Step Beyond Symptom Improvement

In patients with peripheral vascular disease (PVD), the presence of diabetes has been significantly associated with increased failure of critical lower limb ischemia (CLI) treatment, and higher incidence of amputation. This relationship has been attributed mainly to comorbidities and patient characteristics, concomitant peripheral neuropathy and marked microvascular alteration. Also, a high proportion of these patients<a href="https://solaci.org/en/2023/11/24/cilostazol-in-diabetic-patients-with-endovascular-peripheral-revascularization-one-step-beyond-symptom-improvement/" title="Read more" >...</a>

Top